A detailed history of Lindbrook Capital, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Lindbrook Capital, LLC holds 1,665 shares of MREO stock, worth $5,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,665
Previous 1,665 -0.0%
Holding current value
$5,744
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$2.58 - $4.25 $1,638 - $2,698
-635 Reduced 27.61%
1,665 $5,000
Q1 2024

Apr 25, 2024

BUY
$2.3 - $4.05 $5,290 - $9,315
2,300 New
2,300 $7,000
Q3 2021

Nov 05, 2021

SELL
$2.2 - $3.17 $11,000 - $15,850
-5,000 Closed
0 $0
Q2 2021

Jul 27, 2021

BUY
$2.94 - $4.08 $14,700 - $20,400
5,000 New
5,000 $16,000
Q1 2021

Apr 28, 2021

SELL
$2.6 - $4.43 $13,000 - $22,150
-5,000 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$1.95 - $3.6 $9,750 - $18,000
5,000 New
5,000 $18,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $431M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.